MEHD7945A

DRUG5 trials

Sponsors

Genentech, Inc.

Conditions

Colorectal CancerEpithelial Tumors, MalignantHead and Neck CancerNeoplasms

Phase 1

A Study of the Safety and Pharmacokinetics (PK) of MEHD7945A in Participants With Locally Advanced or Metastatic Epithelial Tumors

CompletedNCT01207323

Genentech, Inc.Epithelial Tumors, Malignant

Start: 2010-11-09End: 2018-04-23Updated: 2018-05-01

A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)

CompletedNCT01911598

Genentech, Inc.Head and Neck Cancer

Start: 2013-09-19End: 2017-06-22Updated: 2017-07-06

A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS

CompletedNCT01986166

Genentech, Inc.Neoplasms

Start: 2013-11-30End: 2016-01-31Updated: 2016-07-18

Phase 2

A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck

CompletedNCT01577173

Genentech, Inc.Head and Neck Cancer

Start: 2012-07-31End: 2015-06-30Updated: 2016-11-02

Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)

CompletedNCT01652482

Genentech, Inc.Colorectal Cancer

Start: 2012-10-31End: 2014-11-30Updated: 2016-11-02